INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Institut
University of Chicago
Chicago, Estados UnidosPublicacions en col·laboració amb investigadors/es de University of Chicago (29)
2023
-
Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Haematologica, Vol. 108, Núm. 8, pp. 2192-2204
-
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
Blood, Vol. 141, Núm. 2, pp. 156-167
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
2022
-
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Cancer Cell, Vol. 40, Núm. 11, pp. 1358-1373.e8
-
Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer
Journal of Clinical Oncology, Vol. 37
-
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Blood cancer journal, Vol. 12, Núm. 2, pp. 32
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
-
Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies
European Journal of Cancer, Vol. 174, pp. S31-S32
2021
-
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
The Journal of urology, Vol. 205, Núm. 5, pp. 1361-1371
-
Reply by Authors
The Journal of urology, Vol. 205, Núm. 5, pp. 1371
-
Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19
New England Journal of Medicine, Vol. 385, Núm. 9, pp. 790-802
2020
-
Efficacité de l’enzalutamide (ENZA) + traitement par suppression androgénique (TSA) dans le cancer de la prostate hormonosensible métastatique (mHSPC) en fonction de la localisation des métastases : analyses post-hoc de l’étude ARCHES
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, Vol. 30, Núm. 13, pp. 745
2019
-
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
Haematologica, Vol. 104, Núm. 10, pp. 1935-1949
2017
-
Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future
Cancer Research, Vol. 77, Núm. 6, pp. 1261-1270
2016
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
-
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557
2015
-
A global reference for human genetic variation
Nature, Vol. 526, Núm. 7571, pp. 68-74
-
The small intestinal mucosa acts as a rutin reservoir to extend flavonoid anti-inflammatory activity in experimental ileitis and colitis
Journal of Functional Foods, Vol. 13, pp. 117-125